Atossa Therapeutics, Inc.

ATOS • Biotechnology

$2.52

▼ -0.01 (-0.40%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$22.45M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0Liquidez saludable · 5.53Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 13 ago 2026, 1:04 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$2.52

Change-0.40%

Shares Out8.91M

Market Cap$22.45M

Enterprise Value$-3.64M

52W Range1.70 - 19.35

Beta1.25

P/E-0.60

P/B0.84

P/FCF-0.63

EV/EBITDA0.12

EV/FCF0.10

Price$2.52

Change-0.40%

Shares Out8.91M

Market Cap$22.45M

Enterprise Value$-3.64M

52W Range1.70 - 19.35

Beta1.25

P/E-0.60

P/B0.84

P/FCF-0.63

EV/EBITDA0.12

EV/FCF0.10

Earnings Yield-167.97%

FCF Yield-159.39%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio5.53

Quick Ratio5.53

Target$42.50

Target Upside1586.51%

Target Median$42.50

Target Range10.00 - 75.00

Volume31.17K

Avg Volume123.67K

EPS Surprise0.11

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

70/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

87/100

Por qué este puntaje▼

Nivel de deuda manejable · 0Liquidez saludable · 5.53Rentabilidad débil

Analyst view

Analyst sentiment and price target

ATOS

Analyst sentiment

Based on 5 analyst votes · 2026-09-05

90/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-13

Bajo

$10.00

Promedio

$42.50

Mediana

$42.50

Alto

$75.00

Resumen de la compañía

IPO: 11/8/2012

Industria: Biotechnology

P/B i: 0.84

Deuda / Patrimonio i: 0.00

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 5.53

Ratio rápido: 5.53

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Cigler Tessa

Transacción: 05/12/2026

COMPRA

Cambio

+10,000

Precio

Not reported

Presentación

05/14/2026

Tipo

COMPRA

Galli Stephen J

Transacción: 05/12/2026

COMPRA

Cambio

+10,000

Precio

Not reported

Presentación

05/14/2026

Tipo

COMPRA

Finn Jonathan

Transacción: 05/12/2026

COMPRA

Cambio

+10,000

Precio

Not reported

Presentación

05/14/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Cigler Tessa	COMPRA	+10,000	Not reported	05/12/2026	05/14/2026
Galli Stephen J	COMPRA	+10,000	Not reported	05/12/2026	05/14/2026
Finn Jonathan	COMPRA	+10,000	Not reported	05/12/2026	05/14/2026
Remmel H. Lawrence	COMPRA	+10,000	Not reported	05/12/2026	05/14/2026
Chen Shu-Chih	COMPRA	+10,000	Not reported	05/12/2026	05/14/2026
Steinhart Richard I	COMPRA	+10,000	Not reported	05/12/2026	05/14/2026
QUAY STEVEN C	COMPRA	+65,000	Not reported	03/27/2026	03/31/2026
Daniel Mark James	COMPRA	+63,000	Not reported	03/26/2026	03/30/2026
QUAY STEVEN C	COMPRA	+331,674	Not reported	01/20/2026	01/30/2026
QUAY STEVEN C	COMPRA	+325,203	Not reported	01/20/2026	01/22/2026
QUAY STEVEN C	COMPRA	+950,000	$0.60	01/20/2026	01/22/2026
Daniel Mark James	OTRO	0	Not reported	10/14/2025	10/21/2025
Daniel Mark James	COMPRA	+578,000	$1.03	10/14/2025	10/21/2025
QUAY STEVEN C	COMPRA	+11,239	$0.88	05/21/2025	05/22/2025
Cigler Tessa	COMPRA	+125,000	$0.99	05/15/2025	05/16/2025
Steinhart Richard I	COMPRA	+125,000	$0.99	05/15/2025	05/16/2025
Remmel H. Lawrence	COMPRA	+125,000	$0.99	05/15/2025	05/16/2025
Galli Stephen J	COMPRA	+125,000	$0.99	05/15/2025	05/16/2025
Rees Heather	COMPRA	+543,785	$0.99	05/15/2025	05/16/2025
QUAY STEVEN C	COMPRA	+1,366,062	$0.99	05/15/2025	05/16/2025

Sobre la compañía

Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.

Fuente - Link

Competidores

CGTX CLNN COYA GLSI IMMX ONCY SRZN TIL TVGN WHWK

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended June 30, 2026. "During the quarter, we executed well across the business," stated Dr. Steven Quay, M.D.

PRNewsWire

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models Findings suggest potential for combination with abemaciclib SEATTLE, July 28, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study titled, "Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity in ERα+ breast cancer," reported anti-estrogenic and anti-cancer activity across multiple estrogen receptor-positive breast cancer models, including models harboring clinically relevant activating mutations in ESR1.

PRNewsWire

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome SEATTLE, July 21, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced that a poster presentation titled "Dual estrogen receptor and PKC-β signaling modulation by (Z)-Endoxifen: A mechanism-driven therapeutic strategy for estrogen-driven pathology in McCune-Albright Syndrome" was presented at the AACR Special Conference in Cancer Research: Breaking Barriers in the Fight Against Rare Cancers, which took place July 18-20, 2026, in Vancouver, BC, Canada. Presentation Details Session Type: Poster Session A Date: Saturday, July 18, 2026, 7:30-9:30 pm PT Abstract Number: A010 Location: AACR Special Conference in Cancer Research: Breaking Barriers in the Fight Against Rare Cancers, Vancouver, BC, Canada Poster Title: Dual estrogen receptor and PKC-β signaling modulation by (Z)-Endoxifen: A mechanism-driven therapeutic strategy for estrogen-driven pathology in McCune-Albright Syndrome Presenter: Sandra Hammer, PhD, Atossa Therapeutics Inc. Summary: The poster supports a dual mechanism of action for (Z)-endoxifen in estrogen-driven pathology relevant to McCune Albright Syndrome-associated Peripheral Precocious Puberty (MAS-PPP): the blockade of ER-mediated transcription downstream of autonomous estrogen production and suppression of PKC-β/AKT-associated proliferative and cell-cycle signaling.

PRNewsWire

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of its previously announced registered direct offering of 1,363,637 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,637 shares of Common Stock and short-term Series B warrants to purchase up to 1,363,637 shares of Common Stock (such warrants, collectively, the "Series Warrants") and accompanying Series Warrants. The Series Warrants are exercisable six months following the date of issuance.

PRNewsWire

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,363,638 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,638 shares of Common Stock and short-term Series B warrants to purchase up to 1,363,638 shares of Common Stock (such warrants, collectively, the "Series Warrants") and accompanying Series Warrants in a registered direct offering. The Series Warrants will be exercisable six months following the date of issuance.

PRNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-08	-1.22	-1.11	0.11
2026-03-25	-1.1375	-1.19	-0.0525
2025-11-12	-1.05	-1.05	0
2025-08-12	-0.06	-0.07	-0.01
2025-05-13	-0.06	-0.05	0.01
2025-03-25	-0.06	-0.05	0.01
2024-11-12	-0.06	-0.05	0.01
2024-08-12	-0.05	-0.05	0
2024-05-13	-0.07	-0.05	0.02
2024-04-01	-0.05	-0.06	-0.01
2023-11-13	-0.07	-0.05	0.02
2023-08-14	-0.06	-0.06	0